Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty

Myelin Basic Protein (MBP) (68-82), guinea pig

Copy Product Info
🥰Excellent
Catalog No. TP1092Cas No. 98474-59-0
Alias MBP (68-82), guinea pig

Myelin Basic Protein (MBP) (68-82), guinea pig, is a peptide with the sequence Tyr-Gly-Ser-Leu-Pro-Gln-Lys-Ser-Gln-Arg-Ser-Gln-Asp-Glu-Asn and represents a fragment of myelin basic protein (MBP).

Myelin Basic Protein (MBP) (68-82), guinea pig

Myelin Basic Protein (MBP) (68-82), guinea pig

Copy Product Info
🥰Excellent
Catalog No. TP1092Alias MBP (68-82), guinea pigCas No. 98474-59-0
Myelin Basic Protein (MBP) (68-82), guinea pig, is a peptide with the sequence Tyr-Gly-Ser-Leu-Pro-Gln-Lys-Ser-Gln-Arg-Ser-Gln-Asp-Glu-Asn and represents a fragment of myelin basic protein (MBP).
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$72In StockIn Stock
2 mg$97In StockIn Stock
5 mg$147In StockIn Stock
10 mg$228In StockIn Stock
25 mg$389In StockIn Stock
50 mg$573In StockIn Stock
100 mg$816In StockIn Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:>99.99%
Appearance:Solid
Color:White
Contact us for more batch information

Resource Download

Product Introduction

Bioactivity
Description
Myelin Basic Protein (MBP) (68-82), guinea pig, is a peptide with the sequence Tyr-Gly-Ser-Leu-Pro-Gln-Lys-Ser-Gln-Arg-Ser-Gln-Asp-Glu-Asn and represents a fragment of myelin basic protein (MBP).
In vitro
Multiple sclerosis, the most common autoimmune disorder affecting the central nervous system, is studied by analyzing whole blood samples for the activation capacity of CD4+ and CD8+ T-lymphocytes using human total myelin basic protein (MBP), human MBP 104-118 fragment, and guinea pig MBP (68-82) fragment. A significant increase in activated T-lymphocytes was observed for all three tested MBPs (p<0.01), with the most prominent increase following human total MBP, followed by human 104-118 fragment, and the smallest increase with guinea pig MBP (68-82) (human total MBP>huMBP-104-118>guinea pig MBP (68-82))[1].
In vivo
This study investigates the impact of preemptive bee venom acupuncture (BVA) treatment, starting from the day of myelin basic protein (MBP) (68-82) immunization, on the onset and progression of experimental autoimmune encephalomyelitis (EAE) and associated weight loss. After immunization, rats in the MBP group began showing early signs of EAE, such as partial loss of tail tone, within 5-9 days, progressing to more severe neurological symptoms, including various degrees of limb paralysis, between 10-16 days. In contrast, rats treated with BVA exhibited milder neurological impairments, with a dose-dependent reduction in symptom severity and delayed onset of symptoms (BVA 0.8 mg/kg, 6.4±0.6 days) observed 11-15 days post-immunization. Additionally, the maximum clinical score was significantly lower in the BVA-treated groups (BVA 0.25 mg/kg, 3.7±0.2; BVA 0.8 mg/kg, 2.8±0.3) compared to the untreated MBP group. Moreover, while the MBP group's mean body weight decreased, the MBP + BVA group's mean body weight significantly increased compared to the MBP-only group, highlighting a potential protective effect of BVA against EAE-induced weight loss and symptom severity.
SynonymsMBP (68-82), guinea pig
Chemical Properties
Molecular Weight1736.79
FormulaC71H113N23O28
Cas No.98474-59-0
SmilesC(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@@H](CC(N)=O)C(O)=O)=O)CCC(O)=O)=O)CC(O)=O)=O)CCC(N)=O)=O)CO)=O)CCCNC(=N)N)=O)CCC(N)=O)=O)CO)=O)CCCCN)=O)CCC(N)=O)(=O)[C@H]1N(C([C@@H](NC([C@@H](NC(CNC([C@H](CC2=CC=C(O)C=C2)N)=O)=O)CO)=O)CC(C)C)=O)CCC1
Relative Density.no data available
SequenceTyr-Gly-Ser-Leu-Pro-Gln-Lys-Ser-Gln-Arg-Ser-Gln-Asp-Glu-Asn
Sequence ShortYGSLPQKSQRSQDEN
Storage & Solubility Information
Storagekeep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 10 mM, Sonication is recommended.
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM0.5758 mL2.8789 mL5.7577 mL28.7887 mL
5 mM0.1152 mL0.5758 mL1.1515 mL5.7577 mL
10 mM0.0576 mL0.2879 mL0.5758 mL2.8789 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Related Tags: buy Myelin Basic Protein (MBP) (68-82), guinea pig | purchase Myelin Basic Protein (MBP) (68-82), guinea pig | Myelin Basic Protein (MBP) (68-82), guinea pig cost | order Myelin Basic Protein (MBP) (68-82), guinea pig | Myelin Basic Protein (MBP) (68-82), guinea pig chemical structure | Myelin Basic Protein (MBP) (68-82), guinea pig in vivo | Myelin Basic Protein (MBP) (68-82), guinea pig in vitro | Myelin Basic Protein (MBP) (68-82), guinea pig formula | Myelin Basic Protein (MBP) (68-82), guinea pig molecular weight